Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study

Blood (2021) 137 (18): 2438–2449.

https://doi.org/10.1182/blood.2020009280

Published: 2021

Includes: Supplemental data

Journal Articles

A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP

Blood (2021) 137 (6): 733–742.

https://doi.org/10.1182/blood.2020008021

Published: 2021

Includes: Supplemental data

Journal Articles

Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group

Blood (2020) 136 (19): 2103–2117.

https://doi.org/10.1182/blood.2020005221

Published: 2020

Includes: Supplemental data

Journal Articles

Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival

Blood (2019) 134 (24): 2209–2217.

https://doi.org/10.1182/blood.2019000748

Published: 2019

Includes: Supplemental data

Journal Articles

Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura

Blood (2018) 132 (20): 2143–2153.

https://doi.org/10.1182/blood-2018-04-840090

Published: 2018

Includes: Supplemental data

Journal Articles

Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy–associated C3 glomerulopathy

Sophie Chauvet, Véronique Frémeaux-Bacchi, Florent Petitprez, Alexandre Karras, Laurent Daniel, Stéphane Burtey, Gabriel Choukroun, Yahsou Delmas, Dominique Guerrot, Arnaud François, Moglie Le Quintrec, Vincent Javaugue, David Ribes, Laurence Vrigneaud, Bertrand Arnulf, Jean Michel Goujon, Pierre Ronco, Guy Touchard, Frank Bridoux

Blood (2017) 129 (11): 1437–1447.

https://doi.org/10.1182/blood-2016-08-737163

Published: 2017

Includes: Supplemental data

Journal Articles

Eculizumab Prevents Thrombotic Microangiopathy: Long-Term Follow-up Study of Patients with Atypical Hemolytic Uremic Syndrome

Laurence A. Greenbaum, MDPhD, Yahsou Delmas, MD PhD, Fadi Fakhouri, MD PhD, John F. Kincaid, MD MA, Christoph Licht, MD FRCP(C), FASN, Enrico E. Minetti, MD, Chris Mix, MD, Francois Provôt, MD, Eric Rondeau, MD PhD, Neil Sheerin, BSc, MBBS, MRCP, PhD FRCP, Jimmy Wang, PhD, Laurent E. Weekers, MD, Jan Menne, MD

Blood (2015) 126 (23): 2252.

https://doi.org/10.1182/blood.V126.23.2252.2252

Published: 2015

Journal Articles

Time To Hematologic and Renal Improvements In Atypical Hemolytic Uremic Syndrome Patients With Long Disease Duration and Chronic Kidney Disease (CKD) Treated With Eculizumab

Christoph Licht, MD, Petra Muus, MD, PhD, Christophe Legendre, Yahsou Delmas, MD, Maria Herthelius, MD, Camille L. Bedrosian, MD, Chantel Loirat

Blood (2013) 122 (21): 2186.

https://doi.org/10.1182/blood.V122.21.2186.2186

Published: 2013

Journal Articles

Eculizumab (ECU) in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Progressing Thrombotic Microangiopathy (TMA): 2-Year Data.

Larry Greenbaum, MD, Christophe M. Legendre, MD, Sunil Babu, MD, Richard R. Furman, MD, Neil Sheerin, MD, David Cohen, MD, Frank Eitner, MD, Yahsou Delmas, MD, Camille L. Bedrosian, MD, Chantal Loirat, MD

Blood (2012) 120 (21): 2084.

https://doi.org/10.1182/blood.V120.21.2084.2084

Published: 2012

Journal Articles

Eculizumab (ECU) Safety and Efficacy in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Long Disease Duration and Chronic Kidney Disease (CKD): 2-Year Results

Christoph Licht, MD, Petra Muus, MD, PhD, Christophe M. Legendre, MD, Kenneth W. Douglas, MD, Maryvonne Hourmant, MD, Yahsou Delmas, MD, Maria Herthelius, MD, Antonella Trivelli, MD, Timothy H. J. Goodship, MD, Camille L. Bedrosian, MD, Chantal Loirat, MD

Blood (2012) 120 (21): 985.

https://doi.org/10.1182/blood.V120.21.985.985

Published: 2012

Journal Articles

Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura

Marie Moatti-Cohen, Céline Garrec, Martine Wolf, Pierre Boisseau, Lionel Galicier, Elie Azoulay, Alain Stepanian, Yahsou Delmas, Eric Rondeau, Stéphane Bezieau, Paul Coppo, Agnès Veyradier

Blood (2012) 119 (24): 5888–5897.

https://doi.org/10.1182/blood-2012-02-408914

Published: 2012

Includes: Supplemental data

Journal Articles

Eculizumab Is An Effective Long-Term Treatment In Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Previously Receiving Chronic Plasma Exchange/Infusion (PE/PI): Extension Study Results,

Christoph Licht, MD, Petra Muus, MD, PhD, Christophe Legendre, MD, Kenneth W Douglas, MD, Maryvonne Hourmant, MD, Yahsou Delmas, MD, Maria Herthelius, MD, Antonella Trivelli, MD, Timothy H. J. Goodship, MD, Camille L Bedrosian, MD, Chantal Loirat, MD

Blood (2011) 118 (21): 3303.

https://doi.org/10.1182/blood.V118.21.3303.3303

Published: 2011

Journal Articles

Eculizumab Is An Effective Long-Term Treatment In Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Resistant to Plasma Exchange/Infusion (PE/PI): Results of An Extension Study

Larry Greenbaum, MD, Sunil Babu, MD, Richard R. Furman, MD, Neil Sheerin, MD, David Cohen, MD, Osama Gaber, MD, Frank Eitner, MD, Yahsou Delmas, MD, Chantal Loirat, MD, Camille L Bedrosian, MD, Christophe Legendre, MD

Blood (2011) 118 (21): 193.

https://doi.org/10.1182/blood.V118.21.193.193

Published: 2011

NARROW

Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study

A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP

Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group

Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival

Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura

Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy–associated C3 glomerulopathy

Eculizumab Prevents Thrombotic Microangiopathy: Long-Term Follow-up Study of Patients with Atypical Hemolytic Uremic Syndrome

Time To Hematologic and Renal Improvements In Atypical Hemolytic Uremic Syndrome Patients With Long Disease Duration and Chronic Kidney Disease (CKD) Treated With Eculizumab

Eculizumab (ECU) in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Progressing Thrombotic Microangiopathy (TMA): 2-Year Data.

Eculizumab (ECU) Safety and Efficacy in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Long Disease Duration and Chronic Kidney Disease (CKD): 2-Year Results

Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura

Eculizumab Is An Effective Long-Term Treatment In Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Previously Receiving Chronic Plasma Exchange/Infusion (PE/PI): Extension Study Results,

Eculizumab Is An Effective Long-Term Treatment In Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Resistant to Plasma Exchange/Infusion (PE/PI): Results of An Extension Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only